Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics

NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs® against targets which can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization.

Read more

Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

— Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies —

April 02, 2020 08:30 AM Eastern Daylight Time

SANTA MONICA, Calif. & NEWARK, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).

Read more